Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence